Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eric Shulman

Clinical Cardiac Electrophysiology Downers Grove, IL Medical Doctor

NPI 1598008559 CMS profile 9674480

3825 Highland Ave Fl Tower24, Downers Grove, IL 60515

Open in the dashboard

General payments

$17,801

315 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Shulman of Downers Grove, IL is reported in the CMS Open Payments database as having received $17,801 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,941 26
2024 General $6,105 81
2023 General $5,077 85
2022 General $2,182 80
2021 General $2,497 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Shulman
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Eric Shulman were reported at $1,941. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Eric Shulman Clinical Cardiac Electrophysiology median Middle half National median
2019 $0 $2,361 $585–$8,260 $163
2020 $0 $993 $247–$4,351 $114
2021 $2,497 $1,185 $326–$4,739 $132
2022 $2,182 $2,073 $554–$6,789 $149
2023 $5,077 $2,568 $759–$8,159 $160
2024 $6,105 $2,557 $703–$7,403 $164
2025 $1,941 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $7,076 84 payments
  2. Medtronic, Inc. $2,033 29 payments
  3. Medical Device Business Services, Inc. $1,933 9 payments
  4. Boston Scientific Corporation $1,796 29 payments
  5. Biotronik Inc. $1,436 19 payments
  6. Biosense Webster, Inc. $1,328 36 payments
  7. Janssen Pharmaceuticals, Inc $669 47 payments
  8. E.R. Squibb & Sons, L.L.C. $320 24 payments
  9. Pfizer Inc. $280 15 payments
  10. Edwards Lifesciences Corporation $152 1 payment
  11. Other $778 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,140 286 payments
  2. Travel and Lodging $5,528 28 payments
  3. Consulting Fee $134 1 payment
Products named General payments · program years 2021–2025
  1. AVEIR $3,856 29 payments
  2. Carto 3 $2,614 26 payments
  3. Micra $945 14 payments
  4. XARELTO $669 47 payments
  5. EnSite Precision Cardiac Mapping System $611 5 payments
  6. ENSITE $555 12 payments
  7. Acticor 7 VR-T DX $381 5 payments
  8. Rivacor $321 3 payments
  9. Solia $321 3 payments
  10. Edora $321 3 payments
  11. Other $7,134 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,751

Median for Cardiology: 2,533

Drug cost

$1,114,533

Median for Cardiology: $485,213

Branded share of claims

55.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 940 $810,857
Multaq Dronedarone Hcl Brand 121 $130,069
Xarelto Rivaroxaban Brand 151 $128,412
Dofetilide Generic 52 $12,491
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 42 $9,969
Mexiletine Hcl Generic 62 $5,741
Amiodarone Hcl Generic 365 $4,051
Metoprolol Succinate Generic 317 $3,413
Sotalol Sotalol Hcl Brand 101 $2,564
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 63 $2,424

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$156,259

Medicare's payments for the services billed

Medicare patients

757

Average age 78

Services billed

2,508

375 women, 382 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 69%
Ischemic heart disease 57%
Arthritis 54%
Heart failure 49%
Chronic kidney disease 43%
Diabetes 37%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $100
  • PFIZER INC. $33
$133 940 —
XARELTO
  • Janssen Pharmaceuticals, Inc $44
$44 151 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $25
$25 121 —
VYNDAQEL
  • PFIZER INC. $20
$20 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record